| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-199503150-00002 |
| P698 | PubMed publication ID | 7533955 |
| P2093 | author name string | X Huang | |
| M E Billingham | |||
| V J Dzau | |||
| R E Morris | |||
| R E Pratt | |||
| C R Gregory | |||
| R Shorthouse | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| endothelium | Q111140 | ||
| P304 | page(s) | 655-661 | |
| P577 | publication date | 1995-03-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement | |
| P478 | volume | 59 |
| Q41398474 | Acute rejection of renal allografts: mechanistic insights and therapeutic options |
| Q54982216 | Anti-Inflammatory Effect of Gallic Acid-Eluting Stent in a Porcine Coronary Restenosis Model. |
| Q46874610 | Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. |
| Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
| Q73314726 | Case 6: cardiac allograft vasculopathy |
| Q77177448 | Chronic graft loss: dealing with the vascular alterations in solid organ transplantation |
| Q77724926 | Chronic rejection: an update on the mechanism |
| Q40844675 | Chronic rejection: risk factors, regulation, and possible sites of therapeutic intervention |
| Q44136537 | Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function |
| Q44101454 | Early experience using calcineurin-free protocol in recipients of high-risk cadaver renal transplants |
| Q38525562 | Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study |
| Q44256899 | Effect of sirolimus on ischemia/reperfusion injury in transgenic hypertensive rat. |
| Q45004968 | From sirolimus to the Cypher stent: stages of the victory against restenosis |
| Q35782524 | Identification of differentially expressed genes in rat aortic allograft vasculopathy |
| Q41080817 | Immunosuppressants: cellular and molecular mechanisms of action |
| Q74571379 | Impact of immunosuppression on coronary endothelial function after cardiac transplantation |
| Q44533474 | Improvement of graft vasculopathy following mycophenolate mofetil administration in a child |
| Q35771484 | Management of hyperlipidaemia associated with heart transplantation |
| Q41734033 | Mechanisms and management of acute renal allograft rejection |
| Q33957177 | Mycophenolate mofetil and its mechanisms of action |
| Q43992344 | Mycophenolate mofetil in the treatment of chronic rejection in renal transplantation: 3-year follow-up |
| Q71410931 | Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts |
| Q34346741 | Mycophenolate mofetil: implications for the treatment of glomerular disease |
| Q33639354 | New immunosuppressive drugs and lung transplantation: last or least? |
| Q33806770 | Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens |
| Q50963092 | Preparation and characterization of rapamycin-loaded PLGA coating stent. |
| Q37035703 | Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy |
| Q36752004 | Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. |
| Q35210227 | Randomized trial of immunosuppressive regimens in renal transplantation |
| Q43016836 | Rapamycin eluting stent: the onset of a new era in interventional cardiology |
| Q44420391 | Sirolimus (Rapamycin) Monotherapy Prevents Graft Vascular Disease in Nonhuman Primate Recipients of Orthotopic Aortic Allografts |
| Q44437938 | Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients—a single center experience |
| Q44101547 | Sirolimus-based steroid-free maintenance immunosuppression |
| Q36013104 | Sirolimus-eluting coronary stents: a review |
| Q35125746 | Sirolimus: its discovery, biological properties, and mechanism of action |
| Q35569139 | Stent-based immunosuppressive therapies for the prevention of restenosis |
| Q37387376 | Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study. |
| Q35125788 | Ten years of sirolimus therapy in orthotopic liver transplant recipients |
| Q33732940 | The potential role of rapamycin in pediatric transplantation as observed from adult studies |
| Q35710888 | The use of cyclosporine in renal transplantation |
| Q44482852 | Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts |
| Q44437979 | Use of rapamycin-impregnated stents in coronary arteries |
| Q74084720 | [Heart transplantation--state of the art today] |
| Q74117292 | [The Ravel trial. Zero percent restenosis: A cardiologists dream comes true!] |
Search more.